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Abstract The myelin-associated glycoprotein (MAG) mediates
cell^cell interactions between myelinating glial cells and neurons.
Here we describe the extracellular matrix glycoprotein fibro-
nectin as a binding partner of MAG. It has been identified by
affinity precipitation with MAG-Fc from NG108-15 cells and by
microsequencing of two peptides derived from a 210-kDa protein
band. Western blot analysis showed that fibronectin is also
present in MAG binding partners isolated from N2A (murine
neuroblastoma) cells, rat brain and rat spinal cord. Different
fibronectin isoforms have been isolated from brains of young and
adult rats, indicating that the expression of MAG binding
fibronectin changes during development. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Interactions between neurons and glial cells are essential
during the development of the nervous system. The myelin-
associated glycoprotein (MAG), a molecule expressed by mye-
linating glial cells in the central and peripheral nervous sys-
tems [1], is one of the molecules involved in these processes.
MAG is a member of the siglec family, a group of structurally
related Ig-like proteins, which mediate cell adhesion in a sialic
acid-dependent manner [2,3]. Several functions in glial cell
neuron interaction have been proposed for MAG [4,5].
Although the location of MAG in the periaxonal myelin
membrane and in vitro myelination studies have suggested
that MAG is involved in the initiation of myelination [6],
experiments with MAG knockout mice (MAG3=3 mice) pro-
vided evidence that MAG is not essential for this process.
MAG appears to play an important role in maintaining a
stable interaction between axons and myelin, since in aging
MAG3=3 mice the integrity of myelin and myelinating cells in
the central and peripheral nervous systems deteriorates and
the associated axons show clear signs of degeneration [4,7^10].
In addition, in vitro MAG can in£uence neurite outgrowth
in a bifunctional manner. Whereas it promotes neurite out-
growth of neurons at early stages of development such as
embryonic dorsal root ganglia, it inhibits neurite outgrowth
of neurons at later stages, such as adult dorsal root ganglia or
early postnatal cerebellum [11,12]. This neurite outgrowth in-
hibition activity of MAG has also been demonstrated with cell
lines like NG108-15 neuroblastoma cells [13]. In vivo, MAG
has been shown to inhibit axonal regrowth after a lesion of
adult peripheral nerves [14]. Also in the central nervous sys-
tem, a reduction in the inhibitory potency of myelin from
MAG3=3 mice has been observed [15,16]. However, since
the e¡ects were relatively small, it is clear that other molecules
besides MAG and/or mechanisms are su⁄cient to inhibit re-
generation in the nervous system.
The capability of MAG to in£uence axonal outgrowth and
to stabilize the axon/myelin interaction requires that MAG
binds to receptors on the neuronal cell surface. MAG binding
to neuronal cells is mainly mediated by N-glycans of glyco-
proteins since inhibition of N-glycosylation by swainsonine
has been shown to reduce MAG binding to background levels
[17]. Interactions between MAG and the extracellular matrix
(ECM) proteins collagen [18] and tenascin-R [19] have been
described. Furthermore, a⁄nity precipitation experiments
with MAG-Fc (recombinant extracellular domains of MAG
fused to the Fc fragment of human immunoglobulin) from
di¡erent neuroblastoma cells, isolated neurons and whole
brain or spinal cord of mice and rat have demonstrated that
MAG interacts with several glycoproteins which are likely to
represent neuron-speci¢c MAG binding partners [17,20]
(Strenge et al., submitted). By immunoblot analysis of these
glycoproteins besides tenascin-R, tenascin-C has been identi-
¢ed as a MAG binding partner (Strenge et al., submitted).
However, the molecular nature of the other MAG binding
glycoproteins from neuronal sources still has to be identi¢ed.
Here we demonstrate by microsequencing and immunoblot
analysis that some isoforms of cellular ¢bronectin (Fn) act
as MAG binding partners.
2. Materials and methods
2.1. Reagents
D-[6-3H]Glucosamine-HCl was from Amersham, Braunschweig,
Germany; Pefablock SC was from Biomol, Hamburg, Germany; pro-
tein A-Sepharose beads were from Pharmacia Biotech, Uppsala, Swe-
0014-5793 / 01 / $20.00 ß 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 5 6 6 - 2
E-mail: kstrenge@biochem.uni-kiel.de
E-mail: reinhard.brossmer@urz.uni-heidelberg.de
*Corresponding author. Fax: (49)-421-218 7433.
E-mail: skelm@uni-bremen.de
Abbreviations: ECM, extracellular matrix; FCS, fetal calf serum; Fn,
¢bronectin; MAG, myelin-associated glycoprotein; MAG-Fc, re-
combinant extracellular domains of MAG fused to the Fc fragment
of human immunoglobulin
FEBS 24982 14-6-01
FEBS 24982FEBS Letters 499 (2001) 262^267
den; Super Signal West Dura Extended Duration Substrate was from
Pierce, Rockford, IL, USA; glycopeptidase F (PNGase F) was from
Roche, Mannheim, Germany.
2.2. Antibodies
Horseradish peroxidase-conjugated a⁄nity-puri¢ed donkey anti-
mouse IgG antibody was from Dianova, Hamburg, Germany; mono-
clonal mouse antibody reacting with cellular Fn was from Transduc-
tion Lab, Lexington, KY, USA. In some control experiments, a rabbit
polyclonal antibody against CASPR [21] was used.
2.3. MAG-Fc chimera
The plasmid encoding the Fc chimera containing the N-terminal
three domains of MAG-Fc has been described [22]. Fc chimeras
were produced by transient expression of the plasmid in COS cells
followed by puri¢cation on protein A-Sepharose [23].
2.4. Metabolic labelling of glycans
N2A (murine neuroblastoma) and NG108-15 (hybrid from murine
neuroblastoma and rat glioma cells) were grown in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS)
and 200 mM L-glutamine. For labelling, they were cultured in 6.6 ml
DMEM containing 200 mM L-glutamine, 37.5 Wl FCS, 375 Wl FCS
dialyzed against 20 mM HEPES, pH 7.3, and 20 MBq D-[6-3H]-
glucosamine-HCl for at least 3 days [17].
2.5. Preparation of detergent lysates from cultured cells, rat spinal cord
or brain
Cultured neuroblastoma cells or homogenized brains or spinal
cords were lysed with 20 mM Tris, pH 7.5, containing 150 mM
NaCl, 5 mM EDTA, 1% NP-40 and protease inhibitors (500 WM
Pefablock SC, 0.5 Wg/ml leupeptin and 0.2 Wg/ml trasylol) for 1 h
on ice [17]. The lysate was cleared by centrifugation for 40 min at
100 000Ug.
2.6. A⁄nity precipitation of MAG binding partners
MAG binding partners were a⁄nity precipitated with MAG-Fc
immobilized to protein A-Sepharose beads and eluted from the beads
with 20 mM synthetic sialic acid analogue methyl K-glycoside of 9-
benzoylamino-9-deoxy-5-N-acetylneuraminic acid [24,25] as described
(Strenge et al., submitted).
2.7. PNGase F-treatment
Proteins were denatured by adding SDS and 2-mercaptoethanol to
¢nal concentrations of 1% and 0.5%, respectively, and incubation at
100‡C for 3 min. After cooling, an equal volume of 50 mM Tris
bu¡er, pH 8.5, containing 1% NP-40 and 300 mU PNGase F was
added and the mixture was incubated overnight at 37‡C.
2.8. SDS^PAGE and Western blotting
SDS^PAGE was performed using 8% polyacrylamide gels [26]. Iso-
lated MAG binding partners for sequencing were separated in prep-
arative gels. Silver staining was performed as described [27]. Coomas-
sie staining was performed with 0.05% Coomassie brilliant blue G-250
diluted in water with 10% methanol and 10% acetic acid. For Western
blot analysis, proteins were transferred to nitrocellulose. In the case of
[3H]glucosamine-labelled extracts glycoproteins were detected by
phosphoimaging.
2.9. Microsequencing
In-gel trypsin digestion and mass spectrometric analysis of peptides
were performed by WITA GmbH, Berlin, Germany.
2.10. Immunological analysis on Western blots
For immunodetection, blots were blocked overnight at 4‡C in Tris-
bu¡ered saline containing 0.1% Tween 20 and 5% skim milk (blocking
bu¡er). Blots were washed ¢ve times for 10 min with Tris-bu¡ered
saline containing 0.1% Tween 20 at room temperature, incubated
with anti-Fn antibodies (1:1000) in blocking bu¡er for 1 h at room
temperature, washed as described above and incubated with horse-
radish peroxidase-labelled anti-mouse IgG antibodies (1:20 000) in
blocking bu¡er for 1 h at room temperature. After washing ¢ve
times, they were incubated with Super Signal West Dura Extended
Duration substrate for 5 min and signals were detected by autoradiog-
raphy.
3. Results
This study was performed to characterize one of the major
isolated MAG binding partners, a 210-kDa protein, by micro-
sequencing. MAG binding partners were prepared from N2A
neuroblastoma cells and separated by preparative SDS^PAGE
followed by in-gel trypsin digestion. Although the amount of
proteins was su⁄cient to be detected easily by Coomassie
staining (data not shown), no peptides were obtained after
in-gel trypsin digestion. This could be due to the glycosylation
of the protein, since previous studies have indicated that bind-
ing of MAG is mainly mediated by N-glycans [17], and N-
glycans are known to protect proteins against proteolytic
cleavage. In order to analyze whether the isolated glycopro-
teins carry N-glycans and how much these contribute to their
migration behavior in SDS^PAGE, we treated isolated MAG
binding partners with the N-glycosidase PNGase F prior to
SDS^PAGE side by side with untreated MAG binding part-
ners (Fig. 1A). Signi¢cant changes in electrophoretic mobility
of up to 20 kDa were observed for several proteins after
glycosidase treatment, indicating that several N-glycans could
be removed from MAG binding partners by PNGase F treat-
ment. If Western blots of [3H]glucosamine-labelled MAG
binding partners were treated with PNGase F, most of the
proteins showed a signi¢cant loss of the radioactive label
present in the glycans, whereas proteins on a control-treated
blot remained una¡ected (data not shown). This indicates that
N-glycans contribute signi¢cantly to the overall glycosylation
of these proteins.
Since neurite outgrowth of NG108-15 cells can be inhibited
by MAG [13], it is likely that these cells express functional
MAG binding partners. The protein patterns of isolated
MAG binding partners derived from N2A and NG108-15 cells
are almost identical (Fig. 2), and PNGase F treatment of
MAG binding proteins from NG108-15 cells led to the same
Fig. 1. Glycoproteins isolated by MAG-Fc a⁄nity precipitations
from neuroblastoma cells. A: Silver-stained SDS^PAGE of glyco-
proteins from N2A cells. Lane 1: Untreated MAG binding partners,
lane 2: PNGase F-treated MAG binding partners. Molecular weight
markers are shown in kDa on the right. B: Coomassie-stained prep-
arative SDS^PAGE of PNGase F-treated glycoproteins isolated by
MAG-Fc a⁄nity precipitation from NG108-15 cells. The arrow in-
dicates the protein band which was used for peptide sequencing.
Molecular weight markers are shown in kDa on the right.
FEBS 24982 14-6-01
K. Strenge et al./FEBS Letters 499 (2001) 262^267 263
molecular weight shifts as found for N2A cells (data not
shown). Therefore, NG108-15 cells were used for further prep-
arations. PNGase F-treated glycoproteins isolated from
NG108-15 cells were separated by preparative SDS^PAGE
and visualized with Coomassie blue staining (Fig. 1B). The
210-kDa protein band, indicated by an arrow, was cut out
and peptides were analyzed after in-gel trypsin digestion. Ami-
no acid sequences of two peptides were obtained from this
protein (Table 1A). A search of the SwissProt database re-
vealed that both peptides share 100% identity with murine Fn
(aa 1960^1965 and aa 2241^2249). Fn is an ECM molecule
which exists as an insoluble molecule (cellular Fn) and as a
soluble form in extracellular £uids (plasma Fn). Therefore, it
had to be considered that the isolated protein could represent
a contamination carried over from the FCS in the culture
medium. However, the amino acid sequence of peptide 2 is
100% identical to murine Fn but di¡ers in one amino acid
from the sequence of bovine Fn (Table 1B). This strongly
suggests that the analyzed protein was derived from the mur-
ine cells and not from the FCS of the culture medium.
In order to further characterize the Fn from neuroblastoma
cell extracts, MAG binding partners were isolated from N2A
or NG108-15 cells and 100 Wg of the corresponding cell ex-
tracts were analyzed by staining of Western blots with anti-
bodies directed against cellular Fn. Whereas only weak signals
of two Fn isoforms were detected in both cell extracts, strong
signals of three di¡erent Fn isoforms were detected in isolated
MAG binding partners from both cell lines (Fig. 3). The
bands detected represent Fn, since in control experiments
without the primary anti-Fn antibody or with antibodies of
unrelated speci¢city, these signals were not obtained (data not
shown). This clearly demonstrates that Fn has been enriched
by MAG-Fc a⁄nity precipitation.
The next important question was whether cellular Fn from
primary tissues also interacts with MAG. As a bifunctional
molecule, MAG can either promote or inhibit axonal regen-
eration depending on the age of neurons [11^13,28]. This may
be due to developmentally controlled expression of individual
MAG binding partners which then could mediate di¡erent
intracellular signals. To investigate this possibility, MAG
binding molecules were prepared from extracts of brains
from 1- and 20-day-old rats or adult rats and analyzed by
SDS^PAGE (Fig. 4). Signi¢cant changes in the patterns of
MAG binding partners were observed (Fig. 4A). Compared
to brains from adult animals, MAG binding proteins isolated
from brains of 1-day-old rats showed fewer protein bands. In
addition, some of the proteins from 1-day-old animals were
not detected in precipitates from brains of adult animals. Ex-
amples are a di¡use strong protein band of apparently 300
kDa and proteins of 190, 110, 62 and 58 kDa. Furthermore,
several proteins are more pronounced in preparations from
adult animals or are only found in these preparations (36,
90, 100, 120, 130, 150, 170 and 210 kDa). Changes were
also observed if MAG binding partners from spinal cords of
di¡erent aged rats were analyzed (Fig. 4B). These results in-
dicate for the ¢rst time that a development-dependent regu-
lation of MAG binding proteins occurs in central nervous
system of rats.
In order to investigate whether at all stages of neuronal
development Fn isoforms are available as MAG binding part-
ners, Western blots with preparations from di¡erent develop-
mental stages were analyzed with antibodies directed against
cellular Fn (Fig. 4). In isolated MAG binding partners from
brains (Fig. 4A) of 1- and 20-day-old animals, a band of
approximately 300 kDa represents the main Fn isoform. In
preparations from 20-day-old animals, an additional Fn band
barely entering the gel can be detected. In isolated MAG
binding partners from brains of adult animals, this high mo-
lecular mass band was present only at very low levels, the 300-
kDa Fn isoform was not detectable but two additional Fn
bands of about 210 and 220 kDa appeared. In preparations
from rat spinal cord (Fig. 4B), a clear signal for the 300-kDa
Fig. 2. Phosphoimages of Western blots of [3H]glucosamine-labelled
glycoproteins isolated by MAG-Fc a⁄nity precipitation from N2A
or NG108-15 neuroblastoma cells. Molecular weight markers are
shown in kDa on the right.
Table 1A
Peptide sequences derived from a 210-kDa MAG binding partner
isolated from the murine cell line NG108-15
Peptide 1 ITGLQP
Peptide 2 PGTSTSATL
Table 1B
Comparison of the sequence of mouse peptide 2 with the corre-
sponding murine and bovine sequences from Fn
Fn mouse (2241) PGTSTSATL
Fn bovine (2243) PGTSASATL
Fig. 3. Immunostaining of Western blots of 100 Wg total cell ex-
tracts (E) and the corresponding isolated MAG binding partners (L)
from N2A and NG108-15 cells with antibodies against cellular Fn.
Human cellular Fn (Fn) was used as positive control. The position
of a molecular weight marker with 205 kDa is shown on the right.
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Fn isoform was detected in MAG binding partners isolated
from 6-day-old animals which was even more pronounced in
samples from 10-day-old animals, whereas no Fn was found
in MAG binding partners isolated from adult rat spinal cord.
None of the bands detected with the anti-Fn antibody ap-
peared if the anti-Fn antibody was omitted (Fig. 4A) or an
unrelated antibody was used (Fig. 4B).
The occurrence of these Fn isoforms is also re£ected by the
protein pattern of silver-stained gels of the corresponding
samples. However, it should be noted that the two bands of
apparently 210 and 220 kDa clearly visible on the silver-
stained SDS gel of MAG binding partners from rat spinal
cord apparently did not represent Fn.
4. Discussion
In the present study we have identi¢ed the ECM molecule
Fn as a MAG binding partner by peptide sequencing and by
demonstrating direct binding of Fn to immobilized recombi-
nant MAG-Fc. Fn is a ubiquitous, multifunctional glycopro-
tein which exists as a soluble form in extracellular £uids and
as an insoluble form in the ECM, and plays crucial roles in
many important physiological processes, such as embryogen-
esis, wound healing and cell adhesion [29,30]. It contains bind-
ing sites for other ECM proteins, cell surface receptors, cir-
culating blood proteins, such as ¢brin, and di¡erent
glycosaminoglycans.
For the interaction between MAG and Fn the glycosylation
of Fn plays a pivotal role, since MAG binds with high pref-
erence to K2,3-linked sialic acids on N- and O-glycans [3,22].
Most of the carbohydrate moieties of Fn are complex N-gly-
cans [31]. However, the structures of these glycans depend on
the cell type producing the protein. Most critical for MAG
binding are the sialic acid residues which are K2,3-linked on
cellular Fn, but basically only K2,6-linked on plasma Fn [32].
This explains why in previous studies with plasma Fn, no
interaction with MAG could be shown [33], whereas the ex-
periments described here demonstrate direct interaction be-
tween MAG and cellular Fn from extracts of neuronal cells.
Besides Fn, several other glycoproteins have been isolated
by MAG-Fc a⁄nity precipitations. In principle, this is not
surprising, since the speci¢city of MAG for sialylated glycans
permits the binding of di¡erent glycoproteins. However, the
presence of K2,3-linked sialic acids alone seems not to be
su⁄cient to mediate MAG binding, since only a subset of
brain glycoproteins containing K2,3-linked sialic acids on N-
glycans bind to MAG. This has been shown by a comparison
of MAG binding partners isolated from total brain extract
with the pattern of all glycoproteins containing K2,3-linked
sialic acids present in the extract as detected by lectin overlays
(Strenge et al., submitted). Furthermore, if Fc chimeras of
other siglecs like sialoadhesin (siglec-1) [17] or CD22 (siglec-
2) (Fig. 5) were used in these a⁄nity precipitations, other
band patterns were obtained. In particular, no band with
the molecular mass of the Fn isoforms binding to MAG has
been precipitated with other Fc chimeras. This indicates that
additional structural features are involved in the recognition
events between MAG and the isolated glycoproteins.
A similar pattern of glycoproteins has been isolated from
di¡erent neuronal sources, suggesting that all these proteins
Fig. 4. MAG binding glycoproteins isolated from rat central nerv-
ous system. Glycoproteins isolated by a⁄nity precipitation with
MAG-Fc were separated by SDS^PAGE. Total proteins were visu-
alized by silver staining (lanes S) and Fn (lanes Fn) by immuno-
staining of Western blots with anti-Fn antibodies. Molecular weight
markers are shown in kDa on the right. A: Glycoproteins isolated
by a⁄nity precipitation with MAG-Fc from rat brain extracts
(10 mg protein) of postnatal day 1 (P1), day 20 (P20) or adult
animals as indicated. As a control, immunostaining without the
primary antibody (no pAb) is shown for a preparation from adult
brain. B: Glycoproteins isolated by a⁄nity precipitation with
MAG-Fc from total rat spinal cord extracts (1 mg protein) of post-
natal day 6 (P6), day 10 (P10) or adult animals as indicated. As a
control for the antibody speci¢city an immunostaining of a prepara-
tion from adult spinal cord with anti-CASPR antibody (cAb) is
shown.
Fig. 5. Phosphoimages of Western blots of [3H]glucosamine-labelled
glycoproteins isolated by MAG-Fc or CD22-Fc a⁄nity precipitation
from rat spinal cord neurons. Molecular weight markers are shown
in kDa on the right.
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represent potential neuron-speci¢c MAG binding partners.
Since they can compete for MAG binding sites, this scenario
would allow a relatively complex regulation of MAG-medi-
ated processes involving several binding partners. Elucidating
this regulatory network will be a crucial step towards the
understanding of the functions of these glycoproteins as
MAG binding partner in vivo.
It has recently been shown that the sialic acid binding site
of MAG may only provide a docking function and that an
additional binding site in the Ig domains 4 and 5 mediates the
e¡ects on neurite outgrowth [34]. In the study described here
proteins binding to domains 4 or 5 would not have been
precipitated, since Fc chimeras containing only the three N-
terminal Ig domains of MAG were used. However, in other
experiments with Fc-MAGd1ÿ5, no additional proteins could
be identi¢ed in a⁄nity precipitations from N2A cell extracts
(data not shown).
Of course it remains to be elucidated what role Fn plays as
a MAG binding partner in vivo. In this context it is important
to note that developmental changes in the expression patterns
of MAG binding cellular Fn isoforms have been detected in
the present study. It is most likely that these represent di¡er-
ent splice variants of this molecule. In rat, 12 possible variants
of Fn result from developmentally regulated alternative splic-
ing in the Fn type III domains [35]. The isolation of larger Fn
isoforms from young animals and smaller isoforms from adult
animals by MAG-Fc a⁄nity precipitation is in good agree-
ment with the typical development-dependent splice patterns
found for Fn. Whether this relates to the functional switch of
MAG e¡ects on neurite outgrowth from promotion to inhibi-
tion during development [11] remains to be investigated.
Interestingly, the repair of nerves in the peripheral nervous
system is associated with the reappearance of embryonal
forms of Fn mRNA [36]. This suggests that the re-expression
of embryonic Fn may be important for successful repair in the
peripheral nervous system and that a development- and tissue
repair-dependent expression of di¡erent spliced Fn isoforms
may be involved in regulation of growth processes or stability.
It would be interesting to analyze whether such regulation of
Fn mRNA splicing also occurs after injuries in the central
nervous system.
Although MAG has always been proposed to interact di-
rectly with neuronal cell surface receptors, so far such binding
partners have not been identi¢ed. Instead, di¡erent ECM mol-
ecules have been shown to interact with MAG. Previous in
vitro studies have demonstrated that MAG also interacts with
the ECM proteins collagen [18] and tenascin-R [19]. In addi-
tion, tenascin-R and tenascin-C have been identi¢ed in iso-
lated MAG binding partners from mouse brain and rat spinal
cord by immunoblot analysis (Strenge et al., submitted). Dur-
ing recent years, increasing attention has been paid to the
structural and functional complexity of ECM molecules in
brain [37]. This has led to the concept that ECM components
contribute signi¢cantly to molecular signals in the nervous
system both as di¡usible and as membrane-bound molecules
[38]. It will be interesting to elucidate to what extent interac-
tions between MAG and the di¡erent MAG binding ECM
molecules in£uence interactions between MAG and neurons.
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